Highly reactive ligands, such as the approved drugs used for the treatment of multiple sclerosis, have been described to covalently bind to cysteines within the BTB domain of the E3 ligase Keap1 (Xu et al, 2015). This evidence concerns the gene KEAP1 and multiple sclerosis.